Concomitant Chemoradiotherapy Using Carboplatin, Tegafur-Uracil and Leucovorin for Stage III and IV Head-and-Neck Cancer: Results of GORTEC Phase II Study

Journal Article · Fri Jan 15 04:00:00 EST 2010 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.01.033· OSTI ID:21367599

Fesneau, Melanie; Pointreau, Yoann; Chapet, Sophie ^[1]; Martin, Laurent ^[2]; Pommier, Pascal ^[3]; Alfonsi, Marc ^[4]; Laguerre, Brigitte ^[5]; Feham, Nasreddine ^[6]; Berger, Christine ^[7]; Garaud, Pascal ^[8]; Calais, Gilles ^[1]

---

1. Department of Radiation Oncology, Henry Kaplan Center, Tours (France)
2. Department of Radiation Oncology, Guillaume le Conquerant Center, Le Havre (France)
3. Department of Radiation Oncology, Leon Berard Center, Lyon (France)
4. Department of Radiation Oncology, Sainte Catherine Center, Avignon (France)
5. Department of Radiation Oncology, Eugene Marquis Center, Rennes (France)
6. Department of Radiation Oncology, Louis Pas43teur Hospital, Colmar (France)
7. Department of Radiation Oncology, Saint Jean Center, Saint-Doulchard (France)
8. Department of Radiation Oncology, University Henry Kaplan Center, Tours (France)

Purpose: Concomitant chemoradiotherapy is the standard treatment of locally advanced, nonresectable, head-and-neck squamous cell carcinoma. However, the optimal chemotherapy regimen is still controversial. The objective of this Phase II study was to evaluate the feasibility and efficacy of a concomitant treatment using tegafur-uracil, leucovorin, carboplatin, and radiotherapy. Methods and Materials: A total of 77 patients with head-and-neck squamous cell carcinoma Stage III and IVA were enrolled between October 2003 and July 2005. Of the 77 patients, 72 were eligible. They were treated with tegafur-uracil (300 mg/m{sup 2}/d) and leucovorin (75 mg/d) from Days 1 to 19 and from Days 29 to 47 and carboplatin (70 mg/m{sup 2} intravenously for 4 consecutive days), in three cycles every 21 days. Conventional radiotherapy was delivered to a total dose of 70 Gy in 35 fractions. Results: With a mean follow-up of 22.8 months, the 3-year locoregional control, overall survival and disease-free survival actuarial rate was 33.1%, 41.9%, and 27.2%, respectively. The compliance of the treatment was correct. The main acute toxicity was mucositis, with 62% Grade 3-4. Three patients (4.2%) died of acute toxicity. The incidence and severity of late toxicity was acceptable, with 32% Grade 3 and no Grade 4 toxicity. Conclusion: The protocol of concomitant chemoradiotherapy using tegafur-uracil, leucovorin, and carboplatin for locally advanced unresectable head-and-neck squamous cell carcinoma is feasible. The compliance was correct. The incidence and severity of the acute and late toxicities were acceptable, but not improved. The efficacy of this regimen seems equivalent to the main protocols of concurrent chemoradiotherapy. It represents a possible alternative for patients without an intravenous catheter.

• OSTI ID: 21367599
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 76; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
AZINES
BODY
CARCINOMAS
CHEMOTHERAPY
CITROVORUM FACTOR
COMBINED THERAPY
DISEASES
HEAD
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
MEDICINE
NECK
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
PYRIMIDINES
RADIOLOGY
RADIOTHERAPY
THERAPY
TOXICITY
URACILS